{ "instance": { "rdhl-20220630x6k.htm rdhl-20220630xex99d2.htm": { "axisCustom": 4, "axisStandard": 17, "contextCount": 137, "dts": { "calculationLink": { "local": [ "rdhl-20220630_cal.xml" ] }, "definitionLink": { "local": [ "rdhl-20220630_def.xml" ] }, "inline": { "local": [ "rdhl-20220630x6k.htm", "rdhl-20220630xex99d2.htm" ] }, "labelLink": { "local": [ "rdhl-20220630_lab.xml" ] }, "presentationLink": { "local": [ "rdhl-20220630_pre.xml" ] }, "schema": { "local": [ "rdhl-20220630.xsd", "reference-2009-12-16.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 495, "entityCount": 1, "hidden": { "http://www.redhillbio.com/20220630": 5, "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 6, "http://xbrl.sec.gov/dei/2021q4": 8, "total": 19 }, "keyCustom": 46, "keyStandard": 109, "memberCustom": 38, "memberStandard": 14, "nsprefix": "rdhl", "nsuri": "http://www.redhillbio.com/20220630", "report": { "R1": { "firstAnchor": null, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": null }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - SHARE-BASED PAYMENTS", "role": "http://www.redhillbio.com/role/DisclosureShareBasedPayments", "shortName": "SHARE-BASED PAYMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - NET REVENUES", "role": "http://www.redhillbio.com/role/DisclosureNetRevenues", "shortName": "NET REVENUES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - FINANCIAL INSTRUMENTS", "role": "http://www.redhillbio.com/role/DisclosureFinancialInstruments", "shortName": "FINANCIAL INSTRUMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - SEGMENT INFORMATION", "role": "http://www.redhillbio.com/role/DisclosureSegmentInformation", "shortName": "SEGMENT INFORMATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - EVENT SUBSEQUENT TO JUNE 30, 2022", "role": "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022", "shortName": "EVENT SUBSEQUENT TO JUNE 30, 2022", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Tables)", "role": "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesTables", "shortName": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - SHARE-BASED PAYMENTS (Tables)", "role": "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsTables", "shortName": "SHARE-BASED PAYMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - NET REVENUES (Tables)", "role": "http://www.redhillbio.com/role/DisclosureNetRevenuesTables", "shortName": "NET REVENUES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "rdhl:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - FINANCIAL INSTRUMENTS (Tables)", "role": "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables", "shortName": "FINANCIAL INSTRUMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "rdhl:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30803 - Disclosure - SEGMENT INFORMATION (Tables)", "role": "http://www.redhillbio.com/role/DisclosureSegmentInformationTables", "shortName": "SEGMENT INFORMATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_hb03skIiRUmlkk5JPbbddg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS", "role": "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_hb03skIiRUmlkk5JPbbddg", "decimals": "-3", "lang": null, "name": "ifrs-full:CostOfSales", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_5_1_2022_To_5_31_2022_biD9T3StNEGk_Jx04gi9OQ", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:ShareIssueRelatedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)", "role": "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails", "shortName": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_5_1_2022_To_5_31_2022_biD9T3StNEGk_Jx04gi9OQ", "decimals": "-5", "first": true, "lang": null, "name": "ifrs-full:ShareIssueRelatedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LicenceFeeIncome", "reportCount": 1, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Agreements (Details)", "role": "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "shortName": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "rdhl:SignificantEventsDuringCurrentReportingPeriodTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_3_31_2022_ifrs-full_GeographicalAreasAxis_country_US_vWVvOJLJXk6cOD4QBpWyqQ", "decimals": "-5", "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_6_30_2022_ifrs-full_BorrowingsByNameAxis_rdhl_CreditAgreementMember_-bkuZO8cYkW9nHxhI5LBbQ", "decimals": "3", "first": true, "lang": null, "name": "rdhl:IncreaseDecreaseBorrowingsInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ofmjQsegyUuyJfDct72j4w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Credit Agreement (Details)", "role": "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails", "shortName": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Credit Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_6_30_2022_ifrs-full_BorrowingsByNameAxis_rdhl_CreditAgreementMember_-bkuZO8cYkW9nHxhI5LBbQ", "decimals": "3", "first": true, "lang": null, "name": "rdhl:IncreaseDecreaseBorrowingsInterestRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_ofmjQsegyUuyJfDct72j4w", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock", "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_3_31_2022_qmWp0pUpVkWdzAgOeXfOEw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentContractLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details)", "role": "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails", "shortName": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock", "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_3_31_2022_qmWp0pUpVkWdzAgOeXfOEw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentContractLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsEmployeeStockOptionMember_rdhl_IfrsAwardDateAxis_rdhl_YearOfGrantTwoThousandTwentyTwoMember_fyJlFcB01EOJmGbhN1jyrQ", "decimals": "-3", "first": true, "lang": null, "name": "rdhl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - SHARE-BASED PAYMENTS (Details)", "role": "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails", "shortName": "SHARE-BASED PAYMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsEmployeeStockOptionMember_rdhl_IfrsAwardDateAxis_rdhl_YearOfGrantTwoThousandTwentyTwoMember_fyJlFcB01EOJmGbhN1jyrQ", "decimals": "-3", "first": true, "lang": null, "name": "rdhl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LicenceFeeIncome", "reportCount": 1, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - NET REVENUES (Details)", "role": "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails", "shortName": "NET REVENUES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_hb03skIiRUmlkk5JPbbddg", "decimals": "-3", "lang": null, "name": "ifrs-full:OtherRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "rdhl:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PurchasesFairValueMeasurementLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - FINANCIAL INSTRUMENTS (Details)", "role": "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "shortName": "FINANCIAL INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "rdhl:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PurchasesFairValueMeasurementLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "rdhl:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_6_30_2022_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_CmliBtOvYk6Ukdg3nZZ33A", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_jk9kWlPnJ0if4cyizcJgqg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - FINANCIAL INSTRUMENTS - Significant Unobservable Inputs (Details)", "role": "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails", "shortName": "FINANCIAL INSTRUMENTS - Significant Unobservable Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "rdhl:DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_6_30_2022_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_CmliBtOvYk6Ukdg3nZZ33A", "decimals": "4", "first": true, "lang": null, "name": "ifrs-full:SignificantUnobservableInputLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_jk9kWlPnJ0if4cyizcJgqg", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_hb03skIiRUmlkk5JPbbddg", "decimals": "-3", "first": true, "lang": null, "name": "rdhl:FinanceIncomeCostsNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - SEGMENT INFORMATION (Details)", "role": "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails", "shortName": "SEGMENT INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOperatingSegmentsExplanatory", "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_hb03skIiRUmlkk5JPbbddg", "decimals": "-3", "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_9_29_2022_ifrs-full_CounterpartiesAxis_rdhl_HcrCollateralManagementLlcMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_CashHeldAsSecurityForCreditAgreementMember_E_ewPliG8EmfCHwugVbzXQ", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - EVENT SUBSEQUENT TO JUNE 30, 2022 (Details)", "role": "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details", "shortName": "EVENT SUBSEQUENT TO JUNE 30, 2022 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_9_29_2022_ifrs-full_CounterpartiesAxis_rdhl_HcrCollateralManagementLlcMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_CashHeldAsSecurityForCreditAgreementMember_E_ewPliG8EmfCHwugVbzXQ", "decimals": "-6", "first": true, "lang": null, "name": "ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_6_30_2022_Txe_XU8FYkKnNYu5dk6f3w", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION", "role": "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_6_30_2022_Txe_XU8FYkKnNYu5dk6f3w", "decimals": "-3", "lang": null, "name": "ifrs-full:BalancesWithBanks", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_2CwtZ9jnNE61FqEa6RVvbA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY", "role": "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_2CwtZ9jnNE61FqEa6RVvbA", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_hb03skIiRUmlkk5JPbbddg", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS", "role": "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_hb03skIiRUmlkk5JPbbddg", "decimals": "-3", "lang": null, "name": "ifrs-full:AdjustmentsForSharebasedPayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_Aba-jLA93EGdTaLrgdeZYA", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:DisclosureOfGeneralInformationAboutEntityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - GENERAL", "role": "http://www.redhillbio.com/role/DisclosureGeneral", "shortName": "GENERAL", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:DisclosureOfGeneralInformationAboutEntityTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS", "role": "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatements", "shortName": "BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:SignificantEventsDuringCurrentReportingPeriodTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD", "role": "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriod", "shortName": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:SignificantEventsDuringCurrentReportingPeriodTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES", "role": "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenues", "shortName": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "rdhl-20220630xex99d2.htm", "contextRef": "Duration_1_1_2022_To_6_30_2022_ljZU9QfkMku1jlaKD76Yhw", "decimals": null, "first": true, "lang": "en-US", "name": "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "currency_USD": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "U.S. dollar" } } }, "localname": "USD", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AdrMember": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "American Depositary Receipt (or American Depositary Share, ADS).", "label": "American Depositary Shares, each representing ten Ordinary Shares" } } }, "localname": "AdrMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business contact" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelEmailAddress": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Email address of contact personnel.", "label": "Contact Personnel Email Address" } } }, "localname": "ContactPersonnelEmailAddress", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelFaxNumber": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Fax Number of contact personnel.", "label": "Contact Personnel Fax Number" } } }, "localname": "ContactPersonnelFaxNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AdjustedWeightedAverageShares": { "auth_ref": [ "r44" ], "lang": { "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares outstanding during the period (in thousands)", "verboseLabel": "WEIGHTED AVERAGE OF ORDINARY SHARES (in thousands)" } } }, "localname": "AdjustedWeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "ifrs-full_AdjustmentsForAmortisationExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Adjustments for amortisation expense", "terseLabel": "Amortization of Intangible assets" } } }, "localname": "AdjustmentsForAmortisationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "auth_ref": [ "r68" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Decrease (increase) in inventories" } } }, "localname": "AdjustmentsForDecreaseIncreaseInInventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": { "auth_ref": [ "r68" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in other operating receivables", "verboseLabel": "Decrease (increase) in prepaid expenses and other receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "auth_ref": [ "r68" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade accounts receivable", "terseLabel": "Increase in trade receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for depreciation expense", "terseLabel": "Depreciation" } } }, "localname": "AdjustmentsForDepreciationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceCosts": { "auth_ref": [ "r70" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 13.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance costs", "terseLabel": "Issuance cost in respect of warrants" } } }, "localname": "AdjustmentsForFinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives": { "auth_ref": [ "r71" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 9.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for gains (losses) on change in fair value of derivatives", "negatedLabel": "Fair value (gains) on derivative financial instruments" } } }, "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": { "auth_ref": [ "r69" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Impairment loss (reversal of impairment loss) recognised in profit or loss]" } }, "en-us": { "role": { "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss", "terseLabel": "Amortization and impairment of intangible assets" } } }, "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in derivative financial liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Derivative financial liabilities; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in derivative financial liabilities", "negatedLabel": "Fair value adjustments recognized in profit or loss" } } }, "localname": "AdjustmentsForIncreaseDecreaseInDerivativeFinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r68" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "verboseLabel": "Increase (decrease) in accounts payable" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForInterestExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for interest expense", "terseLabel": "Non-cash interest expenses related to borrowing and payable in respect of intangible assets purchase" } } }, "localname": "AdjustmentsForInterestExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjustments in respect of income and expenses not involving cash flow:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r69" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based compensation to employees and service providers" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "auth_ref": [ "r69", "r77" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 14.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Exchange differences in respect of cash and cash equivalents" } } }, "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital": { "auth_ref": [ "r71" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) other than changes in working capital", "totalLabel": "Total adjustments in respect of income and expenses not involving cash flow" } } }, "localname": "AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r59", "r60", "r90" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated measurement [member]" } } }, "localname": "AggregatedMeasurementMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r16", "r37", "r113", "r121", "r122", "r141", "r159", "r160", "r176", "r177", "r179", "r180" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r36", "r91" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } }, "en-us": { "role": { "label": "All levels of fair value hierarchy [member]" } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r15", "r90", "r91", "r95", "r164", "r167" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AtFairValueMember": { "auth_ref": [ "r59", "r60", "r90" ], "lang": { "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } }, "en-us": { "role": { "label": "At fair value" } } }, "localname": "AtFairValueMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BalancesWithBanks": { "auth_ref": [ "r75" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash balances held at banks." } }, "en-us": { "role": { "label": "Balances with banks", "terseLabel": "Bank deposits" } } }, "localname": "BalancesWithBanks", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r42", "r43" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "LOSS PER ORDINARY SHARE, basic (U.S. dollars):", "negatedTerseLabel": "LOSS PER ORDINARY SHARE, basic (U.S. dollars)" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_BorrowingsByNameAxis": { "auth_ref": [ "r154" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Borrowings by name [axis]" } } }, "localname": "BorrowingsByNameAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsByNameMember": { "auth_ref": [ "r154" ], "lang": { "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings by name [member]" } } }, "localname": "BorrowingsByNameMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BorrowingsInterestRate": { "auth_ref": [ "r154" ], "lang": { "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Interest rate (as a percent)" } } }, "localname": "BorrowingsInterestRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r102", "r104", "r105", "r131", "r154", "r179" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Minimum" } } }, "localname": "BottomOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BrandNamesMember": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing rights to a group of complementary assets such as a trademark (or service mark) and its related trade name, formulas, recipes and technological expertise. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Aemcolo" } } }, "localname": "BrandNamesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalCommitments": { "auth_ref": [ "r8" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of future capital expenditures that the entity is committed to make." } }, "en-us": { "role": { "label": "Capital commitments", "terseLabel": "COMMITMENTS" } } }, "localname": "CapitalCommitments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r13", "r75", "r89" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents, value", "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD", "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r61", "r76" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "FINANCING ACTIVITIES:" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r61", "r76" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "INVESTING ACTIVITIES:" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r61", "r76" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "OPERATING ACTIVITIES:" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of financial assets [axis]" } } }, "localname": "CategoriesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } } }, "localname": "CategoriesOfFinancialLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r40" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r45", "r48", "r97", "r120" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of assets [axis]" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r45", "r97", "r120" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } }, "en-us": { "role": { "label": "Assets [member]" } } }, "localname": "ClassesOfAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r145", "r146", "r148", "r150" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r145", "r146", "r148", "r150" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r55" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfLiabilitiesAxis": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of liabilities [axis]" } } }, "localname": "ClassesOfLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfProvisionsAxis": { "auth_ref": [ "r52" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of other provisions [axis]" } } }, "localname": "ClassesOfProvisionsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails", "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails", "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ifrs-full_CommencementOfMajorLitigationMember": { "auth_ref": [ "r31" ], "lang": { "en": { "role": { "documentation": "This member stands for the commencement of major litigation." } }, "en-us": { "role": { "label": "Commencement of major litigation [member]" } } }, "localname": "CommencementOfMajorLitigationMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ContractLiabilities": { "auth_ref": [ "r106", "r110" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } }, "en-us": { "role": { "label": "Contract liabilities", "terseLabel": "Upfront payment received" } } }, "localname": "ContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ContractualCommitmentsForAcquisitionOfIntangibleAssets": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of contractual commitments for the acquisition of intangible assets." } }, "en-us": { "role": { "label": "Contractual commitments for acquisition of intangible assets", "terseLabel": "Agreement amount payable for acquisition of rights" } } }, "localname": "ContractualCommitmentsForAcquisitionOfIntangibleAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CostOfSales": { "auth_ref": [ "r2", "r28" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } }, "en-us": { "role": { "label": "Cost of sales", "terseLabel": "COST OF REVENUES" } } }, "localname": "CostOfSales", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CounterpartiesAxis": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Counterparties [axis]" } } }, "localname": "CounterpartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CounterpartiesMember": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } }, "en-us": { "role": { "label": "Counterparties [member]" } } }, "localname": "CounterpartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [ "r15" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } }, "en-us": { "role": { "label": "Current accrued expenses and other current liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r17", "r83", "r84" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentContractLiabilities": { "auth_ref": [ "r106" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Current contract liabilities", "periodEndLabel": "Balance at end of the period", "periodStartLabel": "Balance at beginning of the period", "terseLabel": "Allowance for deductions from revenue" } } }, "localname": "CurrentContractLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Current", "terseLabel": "Lease liabilities" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r19", "r83", "r86" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPayablesForPurchaseOfNoncurrentAssets": { "auth_ref": [ "r22" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 6.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables for the purchase of non-current assets. [Refer: Payables for purchase of non-current assets]" } }, "en-us": { "role": { "label": "Current payables for purchase of non-current assets", "terseLabel": "Payable in respect of intangible asset purchase" } } }, "localname": "CurrentPayablesForPurchaseOfNoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentRestrictedCashAndCashEquivalents": { "auth_ref": [ "r15" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 7.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } }, "en-us": { "role": { "label": "Current restricted cash and cash equivalents", "terseLabel": "Restricted cash" } } }, "localname": "CurrentRestrictedCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationExpense": { "auth_ref": [ "r8" ], "calculation": { "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": { "order": 3.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation expense", "terseLabel": "Depreciation" } } }, "localname": "DepreciationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DerivativeFinancialLiabilities": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Derivative financial liabilities", "periodEndLabel": "Derivative liabilities- balance at end of the period", "periodStartLabel": "Derivative liabilities- Balance at beginning of the period" } } }, "localname": "DerivativeFinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DerivativesMember": { "auth_ref": [ "r98", "r103", "r153", "r162" ], "lang": { "en": { "role": { "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Derivative financial instruments." } } }, "localname": "DerivativesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections": { "auth_ref": [ "r50", "r51" ], "lang": { "en": { "role": { "documentation": "The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]" } }, "en-us": { "role": { "label": "Discount rate applied to cash flow projections", "terseLabel": "Discount rate applied to asset's cash flows" } } }, "localname": "DescriptionOfDiscountRatesAppliedToCashFlowProjections", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r133" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "auth_ref": [ "r133" ], "lang": { "en": { "role": { "documentation": "The option life of share options granted." } }, "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Expected useful life to exercise", "verboseLabel": "Expected term" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r133" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r42", "r43" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "LOSS PER ORDINARY SHARE, diluted (U.S. dollars):", "negatedTerseLabel": "LOSS PER ORDINARY SHARE, diluted (U.S. dollars)" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r154" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET REVENUES" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]", "terseLabel": "Schedule of net revenues" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "auth_ref": [ "r175" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for operating segments." } }, "en-us": { "role": { "label": "Disclosure of entity's operating segments [text block]", "terseLabel": "SEGMENT INFORMATION" } } }, "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "EVENT SUBSEQUENT TO JUNE 30, 2022" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } }, "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Schedule of assets and liabilities measured at fair value" } } }, "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Financial instruments" } } }, "localname": "DisclosureOfFinancialInstrumentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "auth_ref": [ "r143", "r146", "r154" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } }, "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } } }, "localname": "DisclosureOfFinancialInstrumentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": { "auth_ref": [ "r134" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)." } }, "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]", "terseLabel": "Schedule of information on RSUs granted" } } }, "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]" } } }, "localname": "DisclosureOfIntangibleAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "auth_ref": [ "r55" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } } }, "localname": "DisclosureOfIntangibleAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EVENT SUBSEQUENT TO JUNE 30, 2022" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of number of shares and weighted averages of exercise prices" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "auth_ref": [ "r131" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]", "terseLabel": "Schedule of information about exercise price and remaining useful life of outstanding options" } } }, "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEGMENT INFORMATION" } } }, "localname": "DisclosureOfOperatingSegmentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": { "auth_ref": [ "r164" ], "lang": { "en": { "role": { "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]" } }, "en-us": { "role": { "label": "Disclosure of operating segments [text block]", "terseLabel": "Schedule of segment profitability and reconciliation to consolidated net loss and comprehensive loss" } } }, "localname": "DisclosureOfOperatingSegmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of operating segments [line items]" } } }, "localname": "DisclosureOfOperatingSegmentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOperatingSegmentsTable": { "auth_ref": [ "r164" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to operating segments." } }, "en-us": { "role": { "label": "Disclosure of operating segments [table]" } } }, "localname": "DisclosureOfOperatingSegmentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of other provisions [line items]" } } }, "localname": "DisclosureOfOtherProvisionsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "auth_ref": [ "r52" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } }, "en-us": { "role": { "label": "Disclosure of other provisions [table]" } } }, "localname": "DisclosureOfOtherProvisionsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r116", "r117" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of revenue from contracts with customers [text block]", "terseLabel": "NET REVENUES" } } }, "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenues" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSegmentsMajorCustomersExplanatory": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "The disclosure of major customers." } }, "en-us": { "role": { "label": "Disclosure of major customers [text block]", "terseLabel": "Schedule of percentages of total net revenues from major customers" } } }, "localname": "DisclosureOfSegmentsMajorCustomersExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r124" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "SHARE-BASED PAYMENTS" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPayments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities." } }, "en-us": { "role": { "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]", "terseLabel": "Schedule of change in derivative financial instrument" } } }, "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHARE-BASED PAYMENTS" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [text block]", "terseLabel": "Schedule of information on options granted" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r72", "r73" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EliminationOfIntersegmentAmountsMember": { "auth_ref": [ "r169", "r174" ], "lang": { "en": { "role": { "documentation": "This member stands for the elimination of intersegment amounts in the reconciliations of total segment amounts to amounts recognised in the entity's financial statements." } }, "en-us": { "role": { "label": "Additional to adjust to GAAP" } } }, "localname": "EliminationOfIntersegmentAmountsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r40" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForSegmentConsolidationItemsMember": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Segment consolidation items' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for segment consolidation items [member]" } } }, "localname": "EntitysTotalForSegmentConsolidationItemsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r15", "r21", "r79", "r81", "r90", "r91", "r95" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equities", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "TOTAL EQUITY" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "EQUITY:" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r15" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "TOTAL LIABILITIES AND EQUITY" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r137" ], "calculation": { "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } }, "en-us": { "role": { "label": "Share-based compensation to employees and service providers" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss": { "auth_ref": [ "r136" ], "lang": { "en": { "role": { "documentation": "The explanation that enables users of financial statements to understand the effect of share-based payment transactions on the entity's profit (loss)." } }, "en-us": { "role": { "label": "Explanation of effect of share-based payments on entity's profit or loss [text block]", "terseLabel": "Schedule of expenses recognized in profit or loss" } } }, "localname": "ExplanationOfEffectOfSharebasedPaymentsOnProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r26" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "rdhl_FinanceIncomeCostsNet", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "terseLabel": "FINANCIAL EXPENSES" } } }, "localname": "FinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r27" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "rdhl_FinanceIncomeCostsNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "terseLabel": "FINANCIAL INCOME" } } }, "localname": "FinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r155" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets at fair value through profits or losses", "verboseLabel": "Financial assets at fair value through profit or loss" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember": { "auth_ref": [ "r155" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss designated as such upon initial recognition or subsequently category. [Refer: Financial assets at fair value through profit or loss, designated upon initial recognition or subsequently]" } }, "en-us": { "role": { "label": "Financial assets at fair value through profit or loss" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsCategoryMember": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, category [member]" } } }, "localname": "FinancialAssetsCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": { "auth_ref": [ "r139" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets pledged as collateral for liabilities or contingent liabilities", "terseLabel": "Restricted cash transferred to collateral bank account" } } }, "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "auth_ref": [ "r157", "r186" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } }, "en-us": { "role": { "label": "Financial liabilities at amortised cost" } } }, "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "auth_ref": [ "r142" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, at fair value", "terseLabel": "Fair value" } } }, "localname": "FinancialLiabilitiesAtFairValue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember": { "auth_ref": [ "r156" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss designated as such upon initial recognition or subsequently category. [Refer: Financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently]" } }, "en-us": { "role": { "label": "Financial liabilities at fair value through profit or loss" } } }, "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial liabilities, category [member]" } } }, "localname": "FinancialLiabilitiesCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FixedInterestRateMember": { "auth_ref": [ "r151" ], "lang": { "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } }, "en-us": { "role": { "label": "Fixed rate" } } }, "localname": "FixedInterestRateMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r140" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 10.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]" } }, "en-us": { "role": { "label": "Gains (losses) on financial assets at fair value through profit or loss", "negatedTerseLabel": "Fair value losses on financial assets at fair value through profit or loss" } } }, "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": { "auth_ref": [ "r93" ], "lang": { "en": { "role": { "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Gains (losses) recognised in profit or loss, fair value measurement, liabilities", "terseLabel": "Fair value adjustments recognized in profit or loss" } } }, "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r34", "r115", "r172", "r181" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r34", "r115", "r172", "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossProfit": { "auth_ref": [ "r2" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]" } }, "en-us": { "role": { "label": "Gross profit", "totalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": { "auth_ref": [ "r101" ], "lang": { "en": { "role": { "documentation": "This member stands for the historical volatility for shares used as a measurement input." } }, "en-us": { "role": { "label": "Volatility" } } }, "localname": "HistoricalVolatilityForSharesMeasurementInputMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ImpairmentLoss": { "auth_ref": [ "r47", "r48" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Impairment loss" } } }, "localname": "ImpairmentLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r75" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "auth_ref": [ "r71" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in working capital." } }, "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTotalLabel": "Total changes in assets and liability items" } } }, "localname": "IncreaseDecreaseInWorkingCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of options." } }, "en-us": { "role": { "label": "Increase (decrease) through exercise of options, equity", "terseLabel": "Exercise of options into ordinary shares" } } }, "localname": "IncreaseDecreaseThroughExerciseOfOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based compensation to employees and service providers" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncrementalFairValueGrantedModifiedSharebasedPaymentArrangements": { "auth_ref": [ "r135" ], "lang": { "en": { "role": { "documentation": "The difference, for modified share-based payment arrangements, between the fair value of the modified equity instrument and that of the original equity instrument, both estimated as at the date of the modification. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Incremental fair value granted, modified share-based payment arrangements", "terseLabel": "Incremental value measured" } } }, "localname": "IncrementalFairValueGrantedModifiedSharebasedPaymentArrangements", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r10", "r54" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r46", "r55", "r120" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill [member]" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestRateMeasurementInputMember": { "auth_ref": [ "r100" ], "lang": { "en": { "role": { "documentation": "This member stands for an interest rate used as a measurement input." } }, "en-us": { "role": { "label": "Risk-free interest rate" } } }, "localname": "InterestRateMeasurementInputMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestRateTypesMember": { "auth_ref": [ "r151" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } }, "en-us": { "role": { "label": "Interest rate types [member]" } } }, "localname": "InterestRateTypesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Inventories": { "auth_ref": [ "r11", "r18", "r38" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 6.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventory" } } }, "localname": "Inventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issuance of ordinary shares and warrants, net of expenses" } } }, "localname": "IssueOfEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r21" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Ordinary shares" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Ordinary share" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } }, "en-us": { "role": { "label": "To directors" } } }, "localname": "KeyManagementPersonnelOfEntityOrParentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r118" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Amount of Lease liability", "terseLabel": "Lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Level1OfFairValueHierarchyMember": { "auth_ref": [ "r36", "r91" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } }, "en-us": { "role": { "label": "Level 1" } } }, "localname": "Level1OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level3OfFairValueHierarchyMember": { "auth_ref": [ "r91" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } }, "en-us": { "role": { "label": "Level 3" } } }, "localname": "Level3OfFairValueHierarchyMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r36", "r91" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r15", "r90", "r91", "r95", "r164", "r168" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [abstract]", "terseLabel": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilitiesMember": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } }, "en-us": { "role": { "label": "Liabilities [member]" } } }, "localname": "LiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LicenceFeeIncome": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from licence fees." } }, "en-us": { "role": { "label": "Licence fee income", "terseLabel": "Licensing revenue", "verboseLabel": "Licensing revenues" } } }, "localname": "LicenceFeeIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails", "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LoansAndReceivablesCategoryMember": { "auth_ref": [ "r185" ], "lang": { "en": { "role": { "documentation": "This member stands for the loans and receivables category of financial assets. [Refer: Loans and receivables]" } }, "en-us": { "role": { "label": "Loans and receivables" } } }, "localname": "LoansAndReceivablesCategoryMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LongtermBorrowings": { "auth_ref": [ "r15" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Non-current portion of non-current borrowings", "terseLabel": "Borrowing" } } }, "localname": "LongtermBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LongtermBorrowingsMember": { "auth_ref": [ "r74", "r78" ], "lang": { "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowing" } } }, "localname": "LongtermBorrowingsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MaterialReconcilingItemsMember": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "This member stands for material adjustments used to reconcile items in the entity's financial statements." } }, "en-us": { "role": { "label": "Material reconciling items [member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r16", "r37", "r113", "r121", "r122", "r141", "r152", "r159", "r176", "r177", "r179", "r180" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r59", "r60", "r90" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details", "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r30" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details", "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r17", "r83", "r85" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "NON-CURRENT ASSETS:" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "auth_ref": [ "r15" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } }, "en-us": { "role": { "label": "Non-current derivative financial liabilities", "periodEndLabel": "Balance at end of the period", "periodStartLabel": "Balance at beginning of the period", "terseLabel": "Derivative financial instruments" } } }, "localname": "NoncurrentDerivativeFinancialLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r118" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r19", "r83", "r87" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "NON-CURRENT LIABILITIES:" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentPayablesForPurchaseOfNoncurrentAssets": { "auth_ref": [ "r22" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current payables for the purchase of non-current assets. [Refer: Payables for purchase of non-current assets]" } }, "en-us": { "role": { "label": "Non-current payables for purchase of non-current assets", "terseLabel": "Payable in respect of intangible assets purchase" } } }, "localname": "NoncurrentPayablesForPurchaseOfNoncurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentRestrictedCashAndCashEquivalents": { "auth_ref": [ "r15" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]" } }, "en-us": { "role": { "label": "Non-current restricted cash and cash equivalents", "terseLabel": "Restricted cash" } } }, "localname": "NoncurrentRestrictedCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "auth_ref": [ "r132", "r134" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Number of RSUs granted" } } }, "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r128" ], "lang": { "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options exercisable in share-based payment arrangement", "terseLabel": "Each option exercisable into number of ordinary shares, ratio" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "auth_ref": [ "r127" ], "lang": { "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options expired in share-based payment arrangement", "verboseLabel": "Number of options cancelled" } } }, "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r126" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "terseLabel": "Shares forfeited" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r125" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of options, extended", "terseLabel": "Number of options granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OperatingSegmentsMember": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "This member stands for operating segments. An operating segment is a component of an entity: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity); (b) whose operating results are regularly reviewed by the entity\u2019s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and (c) for which discrete financial information is available. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Operating segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OptionPricingModelMember": { "auth_ref": [ "r99", "r104" ], "lang": { "en": { "role": { "documentation": "This member stands for a specific valuation technique consistent with the income approach that involves analysing future amounts with option pricing models, such as the Black-Scholes-Merton formula or a binominal model (ie a lattice model), that incorporate present value techniques and reflect both the time value and intrinsic value of an option. [Refer: Income approach [member]]" } }, "en-us": { "role": { "label": "Black and Scholes option pricing model" } } }, "localname": "OptionPricingModelMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r23", "r42" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary shares" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherOperatingIncomeExpense": { "auth_ref": [ "r27" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 5.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other operating income (expense)", "negatedLabel": "OTHER EXPENSES" } } }, "localname": "OtherOperatingIncomeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherProvisionsMember": { "auth_ref": [ "r52" ], "lang": { "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other provisions [member]" } } }, "localname": "OtherProvisionsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherRevenue": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Other revenue", "verboseLabel": "Sales of other products" } } }, "localname": "OtherRevenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r65" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Payment of principal with respect to lease liabilities" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets": { "auth_ref": [ "r184" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the disposal or maturity of available-for-sale financial assets. [Refer: Financial assets available-for-sale]" } }, "en-us": { "role": { "label": "Proceeds from disposal or maturity of available-for-sale financial assets", "terseLabel": "Maturity of non-current bank deposits" } } }, "localname": "ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromExerciseOfOptions": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the exercise of options." } }, "en-us": { "role": { "label": "Proceeds from exercise of options", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromExerciseOfOptions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r66" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "terseLabel": "Proceeds from issuance of ordinary shares and warrants, net of issuance costs" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Net proceeds from issuing shares" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities", "terseLabel": "Proceeds from sale of financial assets at fair value through profit or loss" } } }, "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProductsAndServicesAxis": { "auth_ref": [ "r114", "r170" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Products and services [axis]" } } }, "localname": "ProductsAndServicesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails", "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProductsAndServicesMember": { "auth_ref": [ "r114", "r170" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } }, "en-us": { "role": { "label": "Products and services [member]" } } }, "localname": "ProductsAndServicesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails", "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r3", "r24", "r67", "r80", "r82", "r83", "r164", "r166", "r178", "r183" ], "calculation": { "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 }, "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "negatedTerseLabel": "Consolidated Comprehensive loss", "negatedTotalLabel": "LOSS AND COMPREHENSIVE LOSS FOR THE PERIOD", "terseLabel": "Comprehensive loss" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r27", "r41" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "negatedTotalLabel": "OPERATING LOSS" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r9", "r33" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "terseLabel": "Fixed assets" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Purchase of financial instruments, classified as investing activities", "negatedLabel": "Purchase of financial assets at fair value through profit or loss" } } }, "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Purchase of intangible assets, classified as investing activities", "negatedLabel": "Purchase of intangible assets", "terseLabel": "Upfront payment for acquisition of rights" } } }, "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r62" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchasesFairValueMeasurementLiabilities": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in the fair value measurement of liabilities resulting from purchases of those liabilities. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Purchases, fair value measurement, liabilities", "terseLabel": "Proceeds received during the period" } } }, "localname": "PurchasesFairValueMeasurementLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r102", "r104", "r105", "r131", "r154", "r179" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails", "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r102", "r104", "r105", "r131", "r154", "r179" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails", "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RecoverableAmountOfAssetOrCashgeneratingUnit": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The higher of an asset\u2019s (or cash-generating unit\u2019s) fair value less costs of disposal and its value in use. [Refer: Cash-generating units [member]]" } }, "en-us": { "role": { "label": "Recoverable amount of asset or cash-generating unit", "terseLabel": "Recoverable amount of intangible asset" } } }, "localname": "RecoverableAmountOfAssetOrCashgeneratingUnit", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReportableSegmentsMember": { "auth_ref": [ "r35", "r109", "r164", "r182" ], "lang": { "en": { "role": { "documentation": "This member stands for operating segments for which IFRS 8 requires information to be disclosed. The entity shall report separately information about an operating segment that meets any of the following quantitative thresholds: (a) reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 per cent or more of the combined revenue, internal and external, of all operating segments; (b) the absolute amount of its reported profit or loss is 10 per cent or more of the greater, in absolute amount, of (i) the combined reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments that reported a loss; or (c) assets are 10 per cent or more of the combined assets of all operating segments. Additionally operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed, if management believes that information about the segment would be useful to users of the financial statements. [Refer: Operating segments [member]]" } }, "en-us": { "role": { "label": "Reportable segments [member]" } } }, "localname": "ReportableSegmentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r58" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expenses, net", "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSES" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing components of convertible instruments classified as equity." } }, "en-us": { "role": { "label": "Equity component" } } }, "localname": "ReserveOfEquityComponentOfConvertibleInstrumentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r21", "r29" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r1", "r2", "r25", "r83", "r88", "r138", "r163", "r165", "r170", "r171", "r173" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "terseLabel": "NET REVENUES" } } }, "localname": "Revenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue [abstract]", "verboseLabel": "Revenues" } } }, "localname": "RevenueAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r107", "r108" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Movantik revenues" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods. [Refer: Performance obligations [member]; Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Revenue from performance obligations satisfied or partially satisfied in previous periods", "terseLabel": "Revenue recognized" } } }, "localname": "RevenueFromPerformanceObligationsSatisfiedOrPartiallySatisfiedInPreviousPeriods", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromRenderingOfAdvertisingServices": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from the rendering of advertising services. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Revenue from rendering of advertising services", "terseLabel": "Revenue from promotional services" } } }, "localname": "RevenueFromRenderingOfAdvertisingServices", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromRoyalties": { "auth_ref": [ "r8" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from royalties." } }, "en-us": { "role": { "label": "Royalty income", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromRoyalties", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r119" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "RightofuseAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SalesAndMarketingExpense": { "auth_ref": [ "r27" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } }, "en-us": { "role": { "label": "Sales and marketing expense", "verboseLabel": "SELLING AND MARKETING EXPENSES" } } }, "localname": "SalesAndMarketingExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SegmentConsolidationItemsAxis": { "auth_ref": [ "r164" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Segment consolidation items [axis]" } } }, "localname": "SegmentConsolidationItemsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_SegmentsAxis": { "auth_ref": [ "r35", "r48", "r109", "r164", "r182" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Segments [axis]" } } }, "localname": "SegmentsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_SegmentsMember": { "auth_ref": [ "r35", "r48", "r109", "r169", "r182" ], "lang": { "en": { "role": { "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used." } }, "en-us": { "role": { "label": "Segments [member]" } } }, "localname": "SegmentsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r27" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 4.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to selling, general and administrative activities of the entity." } }, "en-us": { "role": { "label": "Selling, general and administrative expense", "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareIssueRelatedCost": { "auth_ref": [ "r5" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } }, "en-us": { "role": { "label": "Share issuance expenses" } } }, "localname": "ShareIssueRelatedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r21" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium", "terseLabel": "Additional paid-in capital" } } }, "localname": "SharePremium", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Additional paid-in capital" } } }, "localname": "SharePremiumMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Share-based payment arrangements [member]" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermBorrowings": { "auth_ref": [ "r15" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Current borrowings", "terseLabel": "Borrowing" } } }, "localname": "ShorttermBorrowings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SignificantUnobservableInputAssets": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of assets." } }, "en-us": { "role": { "label": "Significant unobservable input" } } }, "localname": "SignificantUnobservableInputAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_SignificantUnobservableInputLiabilities": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } }, "en-us": { "role": { "label": "Significant unobservable input, liabilities", "terseLabel": "Significant unobservable input" } } }, "localname": "SignificantUnobservableInputLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Statement of changes in equity" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r102", "r104", "r105", "r131", "r154", "r179" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Maximum" } } }, "localname": "TopOfRangeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails", "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r14" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Accounts payable" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r12", "r20" ], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade receivables" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeReceivablesMember": { "auth_ref": [ "r8", "r144", "r147", "r149" ], "lang": { "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Other receivables (except prepaid expenses)" } } }, "localname": "TradeReceivablesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": { "auth_ref": [ "r112" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]" } }, "en-us": { "role": { "label": "Transaction price allocated to remaining performance obligations", "terseLabel": "Potential milestone payments" } } }, "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfInterestRatesAxis": { "auth_ref": [ "r151" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of interest rates [axis]" } } }, "localname": "TypesOfInterestRatesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r132" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsAxis": { "auth_ref": [ "r92", "r96" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Unobservable inputs [axis]" } } }, "localname": "UnobservableInputsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_UnobservableInputsMember": { "auth_ref": [ "r92", "r96" ], "lang": { "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } }, "en-us": { "role": { "label": "Unobservable inputs [member]" } } }, "localname": "UnobservableInputsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r53" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, intangible assets other than goodwill", "terseLabel": "Useful life of assets (in years)" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_ValuationTechniquesMember": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Valuation techniques [member]" } } }, "localname": "ValuationTechniquesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Valuation techniques used in fair value measurement [axis]" } } }, "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_WeightedAverageCostOfCapitalMeasurementInputMember": { "auth_ref": [ "r92", "r104" ], "lang": { "en": { "role": { "documentation": "This member stands for the weighted average cost of capital used as a measurement input." } }, "en-us": { "role": { "label": "Weighted average cost of capital" } } }, "localname": "WeightedAverageCostOfCapitalMeasurementInputMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r125" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options granted in share-based payment arrangement", "verboseLabel": "Exercise price for 1 ADS ($)" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment." } }, "en-us": { "role": { "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16", "terseLabel": "Weighted average lessee's incremental annual borrowing rate applied to the lease liabilities" } } }, "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_WeightedAverageMember": { "auth_ref": [ "r102", "r104", "r105", "r154", "r179" ], "lang": { "en": { "role": { "documentation": "This member stands for an average in which each quantity to be averaged is assigned a weight that determines the relative effect of each quantity on the average." } }, "en-us": { "role": { "label": "Weighted average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_WeightedAverageSharePrice2019": { "auth_ref": [ "r130" ], "lang": { "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Average share price" } } }, "localname": "WeightedAverageSharePrice2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "auth_ref": [ "r133" ], "lang": { "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price, share options granted", "terseLabel": "Price of the Company's ordinary shares" } } }, "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r44" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares outstanding", "verboseLabel": "WEIGHTED AVERAGE OF ORDINARY SHARE (in thousands)" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "rdhl_AccountsPayableAndAccruedExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for accounts payable and accrued expenses.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedExpensesMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued expenses and other current liabilities.", "label": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of acquisition of right-of-use assets by means of lease liabilities.", "label": "Acquisition of Right of Use Assets by Means of Lease Liabilities", "terseLabel": "Acquisition of right-of-use assets by means of lease liabilities" } } }, "localname": "AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": { "order": 4.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of adjusted earnings before interest, taxes, depreciation, and amortisation.", "label": "Adjusted Earnings Before Interest, Taxes, Depreciation, And Amortisation", "terseLabel": "Adjusted EBITDA" } } }, "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_AdjustmentsForChangeInInvestmentInCurrentBankDepositsClassifiedAsInvestingActivities": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for change in investment in current bank deposits classified as investing activities.", "label": "Adjustments for Change in Investment in Current Bank Deposits Classified as Investing Activities", "negatedTerseLabel": "Change in investment in current bank deposits" } } }, "localname": "AdjustmentsForChangeInInvestmentInCurrentBankDepositsClassifiedAsInvestingActivities", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease (increase) in accrued expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for decrease (increase) in accrued expenses", "verboseLabel": "Increase (decrease) in accrued expenses and other liabilities" } } }, "localname": "AdjustmentsForDecreaseIncreaseInAccruedExpenses", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_AdjustmentsForForeignExchangeLossesGainsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 12.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for foreign exchange losses (gains) lease liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Foreign Exchange Losses Gains Lease Liabilities", "terseLabel": "Exchange differences in respect of lease liabilities" } } }, "localname": "AdjustmentsForForeignExchangeLossesGainsLeaseLiabilities", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for increase (decrease) in allowance for deductions from revenue.", "label": "Adjustments For Increase Decrease In Allowance For Deductions From Revenue", "terseLabel": "Increase in allowance for deductions from revenue" } } }, "localname": "AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_AdjustmentsForInterestIncomeExpense": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for interest income (expense) to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Interest Income Expense", "negatedLabel": "Non-cash interest expenses related to borrowing and payable in respect of intangible assets purchase" } } }, "localname": "AdjustmentsForInterestIncomeExpense", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_AdjustmentsForRevaluationOfBankDeposits": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 11.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for revaluation of bank deposits.", "label": "Adjustments For Revaluation Of Bank Deposits", "negatedLabel": "Exchange differences and revaluation of bank deposits" } } }, "localname": "AdjustmentsForRevaluationOfBankDeposits", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_AdjustmentsForRoyaltyObligation": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for royalty obligation to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Royalty Obligation", "terseLabel": "Acceleration of royalty obligation" } } }, "localname": "AdjustmentsForRoyaltyObligation", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_AllowanceForDeductionsFromRevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n.a.", "label": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES" } } }, "localname": "AllowanceForDeductionsFromRevenuesAbstract", "nsuri": "http://www.redhillbio.com/20220630", "xbrltype": "stringItemType" }, "rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of allowance for deductions from revenues.", "label": "Allowance For Deductions From Revenues Disclosure [Text Block]", "terseLabel": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES" } } }, "localname": "AllowanceForDeductionsFromRevenuesDisclosureTextBlock", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenues" ], "xbrltype": "textBlockItemType" }, "rdhl_AmericanDepositorySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for American Depository Shares (\"ADS\").", "label": "ADSs" } } }, "localname": "AmericanDepositorySharesMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": { "order": 5.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of amortisation and impairment loss recognised in profit or loss for intangible assets other than goodwill.", "label": "Amortisation and Impairment Loss Recognised in Profit or Loss, Intangible Assets Other Than Goodwill", "terseLabel": "Amortization and impairment of intangible assets" } } }, "localname": "AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_AmountsClassifiedToEquityOfFairvalueMeasurementLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The Increase or decrease in the fair value measurement of liabilities amount classified to equity.", "label": "Amounts classified to Equity Of Fairvalue Measurement Liabilities", "terseLabel": "Exercise of derivative into shares" } } }, "localname": "AmountsClassifiedToEquityOfFairvalueMeasurementLiabilities", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails", "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_AnnualRentalFirstFourYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for annual rental during a time band of the first four years.", "label": "Yearly rental, first four years" } } }, "localname": "AnnualRentalFirstFourYearsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "rdhl_AnnualRentalNextEightYearsFollowingFirstFourYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for annual rental during a time band of the next eight years following the first four years.", "label": "Yearly rental, next eight years" } } }, "localname": "AnnualRentalNextEightYearsFollowingFirstFourYearsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "rdhl_ArrangementsTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item is to be populated with the collective of types (categories) of arrangements or agreements of the entity applicable to its revenue-generating activities or operations.", "label": "Arrangements Transactions [Member]" } } }, "localname": "ArrangementsTransactionsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "domainItemType" }, "rdhl_AstrazenecaAbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for AstraZeneca AB.", "label": "AstraZeneca AB" } } }, "localname": "AstrazenecaAbMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "rdhl_AtMarketEquityOfferingProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for at-the-market equity offering program.", "label": "At-the-market equity offering program" } } }, "localname": "AtMarketEquityOfferingProgramMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "rdhl_AuthorisedProceedsFromShareIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The authorised proceeds from issue of shares.", "label": "Authorised Proceeds From Share Issuance", "terseLabel": "Authorised proceeds from issuance of shares" } } }, "localname": "AuthorisedProceedsFromShareIssuance", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_BankDepositsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for bank deposits.", "label": "Bank deposits" } } }, "localname": "BankDepositsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_BondCouponMaturityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maturity term for bond coupon payments.", "label": "Bond Coupon Maturity Term", "terseLabel": "Maturity periods for bond coupon payments" } } }, "localname": "BondCouponMaturityTerm", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "durationItemType" }, "rdhl_BorrowingsCovenantNetSalesRequirement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents borrowings covenant to maintain net sales amount.", "label": "Borrowings Covenant Net Sales Requirement", "terseLabel": "Borrowings covenant, minimum net sales requirement" } } }, "localname": "BorrowingsCovenantNetSalesRequirement", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_CashAndEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for cash and cash equivalents.", "label": "Cash and cash equivalents." } } }, "localname": "CashAndEquivalentsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_CashHeldAsSecurityForCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for cash held as security for credit agreement.", "label": "Cash held in account as security for credit agreement" } } }, "localname": "CashHeldAsSecurityForCreditAgreementMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "domainItemType" }, "rdhl_ChangesInAssetsAndLiabilityItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Changes In Assets And Liability Items [Abstract]", "terseLabel": "Changes in assets and liability items:" } } }, "localname": "ChangesInAssetsAndLiabilityItemsAbstract", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "rdhl_CommercialOperationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the Commercial Operations operating segment.", "label": "Commercial Operations" } } }, "localname": "CommercialOperationMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "rdhl_CommercializationRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of revenue arising from commercialization.", "label": "Commercialization Revenue", "terseLabel": "Revenue from commercialization of products" } } }, "localname": "CommercializationRevenue", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_ContractWithCustomerLiabilityCurrentDecreaseThroughUtilization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of decrease in current contract liability through utilization.", "label": "Contract With Customer Liability Current, Decrease Through Utilization", "terseLabel": "Decreases (utilized)" } } }, "localname": "ContractWithCustomerLiabilityCurrentDecreaseThroughUtilization", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_ContractWithCustomerLiabilityCurrentIncreaseDecreaseThroughOtherAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase (decrease) in current contract with customer liability through other adjustments.", "label": "Contract With Customer Liability Current, Increase (Decrease) Through Other Adjustments", "terseLabel": "Adjustments" } } }, "localname": "ContractWithCustomerLiabilityCurrentIncreaseDecreaseThroughOtherAdjustments", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_ContractWithCustomerLiabilityCurrentIncreaseThroughAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of increase in current contract with customer liability through additions.", "label": "Contract with Customer Liability, Current, Increase through Additions", "terseLabel": "Increases" } } }, "localname": "ContractWithCustomerLiabilityCurrentIncreaseThroughAdditions", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_ContractualLifeOfShareBasedAwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The contractual life of awards in a share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Contractual Life Of Share Based Awards", "terseLabel": "Option term" } } }, "localname": "ContractualLifeOfShareBasedAwards", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "durationItemType" }, "rdhl_CreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for credit agreement.", "label": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "rdhl_CurrentPrepaidExpensesAndReceivables": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised, and the amount of receivables.", "label": "Current Prepaid Expenses and Receivables", "terseLabel": "Prepaid expenses and other receivables" } } }, "localname": "CurrentPrepaidExpensesAndReceivables", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "rdhl_DateOfGrantAprilTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant April 2021.", "label": "April 2021" } } }, "localname": "DateOfGrantAprilTwoThousandTwentyOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantAprilTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant April 2022.", "label": "April 2022" } } }, "localname": "DateOfGrantAprilTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantAugustTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant august 2020.", "label": "August 2020" } } }, "localname": "DateOfGrantAugustTwoThousandTwentyMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantAugustTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant August 2021.", "label": "August 2021" } } }, "localname": "DateOfGrantAugustTwoThousandTwentyOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantDecemberTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant December 2019.", "label": "December 2019" } } }, "localname": "DateOfGrantDecemberTwoThousandNineteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantDecemberTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant December 2021.", "label": "December 2021" } } }, "localname": "DateOfGrantDecemberTwoThousandTwentyOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantFebruaryTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the date of grant February 2019", "label": "February 2019" } } }, "localname": "DateOfGrantFebruaryTwoThousandNineteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantFebruaryTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant February 2020.", "label": "February 2020" } } }, "localname": "DateOfGrantFebruaryTwoThousandTwentyMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantFebruaryTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant February 2022.", "label": "February 2022" } } }, "localname": "DateOfGrantFebruaryTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantJanuaryTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the date of grant January 2020.", "label": "January 2020" } } }, "localname": "DateOfGrantJanuaryTwoThousandTwentyMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantJanuaryTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant January 2022.", "label": "January 2022" } } }, "localname": "DateOfGrantJanuaryTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantJulyTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant July 2019.", "label": "July 2019" } } }, "localname": "DateOfGrantJulyTwoThousandNineteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantJulyTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant July 2020.", "label": "July 2020" } } }, "localname": "DateOfGrantJulyTwoThousandTwentyMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantJulyTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant July 2021.", "label": "July 2021" } } }, "localname": "DateOfGrantJulyTwoThousandTwentyOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantJuneTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the date of grant June 2019.", "label": "June 2019" } } }, "localname": "DateOfGrantJuneTwoThousandNineteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantJuneTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant June 2020.", "label": "June 2020" } } }, "localname": "DateOfGrantJuneTwoThousandTwentyMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantJuneTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant June 2022.", "label": "June 2022" } } }, "localname": "DateOfGrantJuneTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantMarchTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant March 2020.", "label": "March 2020" } } }, "localname": "DateOfGrantMarchTwoThousandTwentyMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantMarchTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant March 2021.", "label": "March 2021" } } }, "localname": "DateOfGrantMarchTwoThousandTwentyOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantMarchTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant March 2022.", "label": "March 2022" } } }, "localname": "DateOfGrantMarchTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantMayTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the date of grant May 2019.", "label": "May 2019" } } }, "localname": "DateOfGrantMayTwoThousandNineteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantMayTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant May 2020.", "label": "May 2020" } } }, "localname": "DateOfGrantMayTwoThousandTwentyMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantMayTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant May 2021.", "label": "May 2021" } } }, "localname": "DateOfGrantMayTwoThousandTwentyOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantMayTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant May 2022.", "label": "May 2022" } } }, "localname": "DateOfGrantMayTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantNovemberTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant November 2019.", "label": "November 2019" } } }, "localname": "DateOfGrantNovemberTwoThousandNineteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantNovemberTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant November 2020.", "label": "November 2020" } } }, "localname": "DateOfGrantNovemberTwoThousandTwentyMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantNovemberTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant November 2021.", "label": "November 2021" } } }, "localname": "DateOfGrantNovemberTwoThousandTwentyOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantSeptemberTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant September 2019.", "label": "September 2019" } } }, "localname": "DateOfGrantSeptemberTwoThousandNineteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DateOfGrantSeptemberTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the date of grant September 2021.", "label": "September 2021" } } }, "localname": "DateOfGrantSeptemberTwoThousandTwentyOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS" } } }, "localname": "DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract", "nsuri": "http://www.redhillbio.com/20220630", "xbrltype": "stringItemType" }, "rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for basis of preparation of condensed consolidated interim financial statements.", "label": "Disclosure Of Basis Of Preparation Of Condensed Consolidated Interim Financial Statements [Text Block]", "terseLabel": "BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS" } } }, "localname": "DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatements" ], "xbrltype": "textBlockItemType" }, "rdhl_DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of the entity's financial instruments and financial risk management practices and policies.", "label": "Disclosure Of Financial Instruments And Financial Risk Management [Text Block]", "verboseLabel": "FINANCIAL INSTRUMENTS" } } }, "localname": "DisclosureOfFinancialInstrumentsAndFinancialRiskManagementTextBlock", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "rdhl_DisclosureOfGeneralInformationAboutEntityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of general information about the entity.", "label": "Disclosure Of General Information About The Entity [Text Block]", "terseLabel": "GENERAL" } } }, "localname": "DisclosureOfGeneralInformationAboutEntityTextBlock", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureGeneral" ], "xbrltype": "textBlockItemType" }, "rdhl_EachFiscalQuarterStartingFiscalQuarterEndingJuneThirtyTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for each fiscal quarter starting the fiscal quarter ending June 30, 2022.", "label": "Each fiscal quarter starting the fiscal quarter ending June 30, 2022" } } }, "localname": "EachFiscalQuarterStartingFiscalQuarterEndingJuneThirtyTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "rdhl_EmployeeStockOptionAndRestrictedStockUnitsRsuMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for employee stock options and restricted stuck units (RSUs).", "label": "Stock Options and RSUs" } } }, "localname": "EmployeeStockOptionAndRestrictedStockUnitsRsuMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_EsomeprazoleStrontiumDelayedReleaseCapsulesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Esomeprazole Strontium delayed-release capsules.", "label": "Esomeprazole" } } }, "localname": "EsomeprazoleStrontiumDelayedReleaseCapsulesMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "domainItemType" }, "rdhl_EstimatedAnnualMinimumOperatingLeasePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated annual rental expense for the reporting period incurred under operating leases.", "label": "Estimated Annual Minimum Operating Lease Payments", "terseLabel": "Approximate yearly rental expenses" } } }, "localname": "EstimatedAnnualMinimumOperatingLeasePayments", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_ExclusiveLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Exclusive License Agreement.", "label": "Exclusive License Agreement [Member]" } } }, "localname": "ExclusiveLicenseAgreementMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "domainItemType" }, "rdhl_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administration.", "label": "Expense From Sharebased Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administration", "terseLabel": "Allocated share-based compensation expense" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministration", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_FairValueAssumptionsAverageStandardDeviation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average standard deviation assumption used in valuing an instrument.", "label": "Fair Value Assumptions Average Standard Deviation", "terseLabel": "Average standard deviation" } } }, "localname": "FairValueAssumptionsAverageStandardDeviation", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "percentItemType" }, "rdhl_FairValueAtGrantDateEquityInstrumentsGranted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of equity instruments on the date of grant.", "label": "Fair Value at Grant Date Equity Instruments Granted", "terseLabel": "Fair value of options on date of grant in U.S. dollars in thousands" } } }, "localname": "FairValueAtGrantDateEquityInstrumentsGranted", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_FinanceIncomeCostsNet": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 }, "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of net income or net cost associated with interest and other financing activities of the entity.", "label": "Finance Income Costs Net", "negatedLabel": "Financial expenses (income), net", "negatedTotalLabel": "FINANCIAL EXPENSES, net" } } }, "localname": "FinanceIncomeCostsNet", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "rdhl_GaelanMedicalTradeLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Gaelan Medical Trade LLC.", "label": "Gaelan" } } }, "localname": "GaelanMedicalTradeLlcMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "rdhl_GeneralInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "GENERAL" } } }, "localname": "GeneralInformationAbstract", "nsuri": "http://www.redhillbio.com/20220630", "xbrltype": "stringItemType" }, "rdhl_GrossProceedsFromIssuingShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The gross cash inflow from issuing shares.", "label": "Gross Proceeds From Issuing Shares", "terseLabel": "Gross consideration" } } }, "localname": "GrossProceedsFromIssuingShares", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_HcrCollateralManagementLlcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for HCR Collateral Management, LLC.", "label": "HCRM" } } }, "localname": "HcrCollateralManagementLlcMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "domainItemType" }, "rdhl_IfrsAccountsPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts payable" } } }, "localname": "IfrsAccountsPayableMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsAwardDateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "IFRS Award Date [Axis]" } } }, "localname": "IfrsAwardDateAxis", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "rdhl_IfrsAwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "IFRS Award Date [Domain]" } } }, "localname": "IfrsAwardDateDomain", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "IFRS Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "SUPPLEMENTARY INFORMATION ON NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "IfrsCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "IFRS Class Of Warrant Or Right Exercise Price Of Warrants Or Rights", "terseLabel": "Warrants exercise price" } } }, "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "perShareItemType" }, "rdhl_IfrsDecreaseInRestrictedCash": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.", "label": "IFRS Decrease In Restricted Cash", "terseLabel": "Decrease in restricted cash" } } }, "localname": "IfrsDecreaseInRestrictedCash", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_IfrsEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.", "label": "Stock Options" } } }, "localname": "IfrsEmployeeStockOptionMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Risk-free interest rate assumption used in valuing an instrument.", "label": "IFRS Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "IfrsFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "percentItemType" }, "rdhl_IfrsIncreaseInRestrictedCash": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.", "label": "IFRS Increase In Restricted Cash", "negatedLabel": "Increase in restricted cash" } } }, "localname": "IfrsIncreaseInRestrictedCash", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_IfrsLesseeOperatingLeaseTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Ifrs Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "IfrsLesseeOperatingLeaseTermOfContract", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "durationItemType" }, "rdhl_IfrsNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "IFRS Noncash Or Part Noncash Acquisition Intangible Assets Acquired 1", "terseLabel": "Purchase of an intangible asset in consideration for issuance of shares" } } }, "localname": "IfrsNoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_IfrsNumberOfReportableSegments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "IFRS Number Of Reportable Segments", "terseLabel": "Number of segments" } } }, "localname": "IfrsNumberOfReportableSegments", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "integerItemType" }, "rdhl_IfrsRestrictedStockUnitsRsuMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "RSUs" } } }, "localname": "IfrsRestrictedStockUnitsRsuMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "IFRS Scenario Unspecified [Domain]" } } }, "localname": "IfrsScenarioUnspecifiedDomain", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for which vesting was accelerated.", "label": "IFRS Share-Based Compensation Arrangement By Share-Based Payment Award Accelerated Vesting Number", "terseLabel": "Acceleration of unvested options (shares)" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingNumber", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "sharesItemType" }, "rdhl_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "IFRS Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period", "terseLabel": "Service period" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "durationItemType" }, "rdhl_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "IFRS Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Vesting period" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "durationItemType" }, "rdhl_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of share-based compensation awards.", "label": "IFRS Share-Based Compensation Arrangement By Share-Based Payment Award Award Vesting Rights Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "rdhl_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "IFRS Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "rdhl_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "IFRS Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Shares approved for grant" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "sharesItemType" }, "rdhl_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithExtendedExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IFRS Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares With Extended Exercise Period", "label": "IFRS Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares With Extended Exercise Period", "terseLabel": "Number of shares that were granted an extension" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesWithExtendedExercisePeriod", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "sharesItemType" }, "rdhl_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "IFRS Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Options exercisable, exercise price" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "perShareItemType" }, "rdhl_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "IFRS Share-based Compensation Arrangement By Share-based Payment Award Options Vested Number Of Shares", "terseLabel": "Number of fully-vested options" } } }, "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "sharesItemType" }, "rdhl_IfrsShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting, services exceeding one year" } } }, "localname": "IfrsShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting, one year following grant" } } }, "localname": "IfrsShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting, services not exceeding one year" } } }, "localname": "IfrsShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsSharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "IFRS Shares Issued Price Per Share", "terseLabel": "Purchase price (per share)" } } }, "localname": "IfrsSharesIssuedPricePerShare", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "perShareItemType" }, "rdhl_IfrsStatementScenarioAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "IFRS Statement Scenario [Axis]" } } }, "localname": "IfrsStatementScenarioAxis", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "stringItemType" }, "rdhl_IfrsTradeAccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.", "label": "Trade receivables" } } }, "localname": "IfrsTradeAccountsReceivableMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsVestingAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Axis]" } } }, "localname": "IfrsVestingAxis", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "stringItemType" }, "rdhl_IfrsVestingDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Domain]" } } }, "localname": "IfrsVestingDomain", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants" } } }, "localname": "IfrsWarrantMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IfrsWarrantsAndRightsOutstandingTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "IFRS Warrants And Rights Outstanding Term", "terseLabel": "Warrants term" } } }, "localname": "IfrsWarrantsAndRightsOutstandingTerm", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "durationItemType" }, "rdhl_IncreaseDecreaseBorrowingsInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) of the interest rate on borrowings.", "label": "Increase Decrease Borrowings Interest Rate", "terseLabel": "Increase to interest rate (as a percent)" } } }, "localname": "IncreaseDecreaseBorrowingsInterestRate", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "percentItemType" }, "rdhl_IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseInDesignatedRiskComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in a financial instrument as a result of an increase in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations.", "label": "Increase Decrease In Financial Instrument Due To Reasonably Possible Increase In Designated Risk Component", "terseLabel": "Additional expense that would have been recognized" } } }, "localname": "IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseInDesignatedRiskComponent", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_IncreaseDecreaseThroughSharebasedPaymentForIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment for intangible assets.", "label": "Increase Decrease Through Sharebased Payment For Intangible Assets", "terseLabel": "Share-based compensation in consideration for intangible assets" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentForIntangibleAssets", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "rdhl_IncreaseDecreaseThroughWarrantsExpiration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the expiration of warrants.", "label": "Increase (Decrease) Through Warrants Expiration", "terseLabel": "Warrants expiration" } } }, "localname": "IncreaseDecreaseThroughWarrantsExpiration", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "rdhl_IncreaseInContractualCommitmentsForAcquisitionOfIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase in the amount of contractual commitments for the acquisition of intangible assets.", "label": "Increase In Contractual Commitments For Acquisition Of Intangible Assets", "terseLabel": "Increase in agreement amount payable for acquisition of rights" } } }, "localname": "IncreaseInContractualCommitmentsForAcquisitionOfIntangibleAssets", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_InventoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventory" } } }, "localname": "InventoryMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IssuanceTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of shares issuance.", "label": "Issuance tranche one" } } }, "localname": "IssuanceTrancheOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "rdhl_IssuanceTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of shares issuance.", "label": "Issuance tranche two" } } }, "localname": "IssuanceTrancheTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "rdhl_KukboCo.Ltd.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Kukbo Co. Ltd.", "label": "Kukbo Co. Ltd." } } }, "localname": "KukboCo.Ltd.Member", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "rdhl_LiborFloorRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for 3-month LIBOR floor rate.", "label": "3-month LIBOR floor rate" } } }, "localname": "LiborFloorRateMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "rdhl_LicenseAgreementUpfrontPaymentsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from upfront payments related to license agreement.", "label": "License Agreement, Upfront Payments Received", "terseLabel": "Upfront payments received" } } }, "localname": "LicenseAgreementUpfrontPaymentsReceived", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_LongTermBorrowingTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of long-term borrowings transaction costs.", "label": "Long Term Borrowing Transaction Costs", "terseLabel": "Long-term borrowing transaction costs" } } }, "localname": "LongTermBorrowingTransactionCosts", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_LossContingencyDefaultAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of default in loss contingency.", "label": "Loss Contingency Default Amount", "terseLabel": "Default amount" } } }, "localname": "LossContingencyDefaultAmount", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "monetaryItemType" }, "rdhl_MaturityPeriodsForCashBalancesInHighlyRatedBankDeposits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maturity periods for cash balances in highly-rated bank deposits.", "label": "Maturity Periods For Cash Balances In Highly Rated Bank Deposits", "terseLabel": "Maturity periods for cash balances in highly-rated bank deposits" } } }, "localname": "MaturityPeriodsForCashBalancesInHighlyRatedBankDeposits", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "durationItemType" }, "rdhl_MilestonesToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payments to be paid to collaborative partner.", "label": "Milestones to be paid" } } }, "localname": "MilestonesToBePaid", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_MovantikMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Movantik prescription medicine.", "label": "Movantik" } } }, "localname": "MovantikMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "rdhl_MovementInRestrictedCash": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents movement in restricted cash.", "label": "Movement In Restricted Cash", "negatedLabel": "Movement in restricted cash" } } }, "localname": "MovementInRestrictedCash", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_NoncurrentRoyaltyObligation": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent royalty obligation.", "label": "Noncurrent Royalty Obligation", "terseLabel": "Royalty obligation" } } }, "localname": "NoncurrentRoyaltyObligation", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "rdhl_NumberOfFullyVestedOptionsExtendedInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of fully-vested share options extended in share-based payment arrangement.", "label": "Number Of Fully Vested Options Extended In Share Based Payment Arrangement", "terseLabel": "Number options extended" } } }, "localname": "NumberOfFullyVestedOptionsExtendedInShareBasedPaymentArrangement", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "decimalItemType" }, "rdhl_NumberOfLicenseAgreementTerritories": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of territories under license agreements.", "label": "Number Of License Agreement Territories", "terseLabel": "Number of license agreement territories" } } }, "localname": "NumberOfLicenseAgreementTerritories", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" ], "xbrltype": "integerItemType" }, "rdhl_OptionsOriginallyScheduledToExpireInAugustTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension of options originally scheduled to expire in August 2018.", "label": "Extension of options originally scheduled to expire in August 2018" } } }, "localname": "OptionsOriginallyScheduledToExpireInAugustTwoThousandEighteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_OptionsOriginallyScheduledToExpireInFebruary2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options originally scheduled to expire in February 2019 [member]", "label": "Extension of options originally scheduled to expire in February 2019" } } }, "localname": "OptionsOriginallyScheduledToExpireInFebruary2019Member", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_OptionsOriginallyScheduledToExpireInFebruaryTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension of options originally scheduled to expire in February 2018.", "label": "Extension of options originally scheduled to expire in February 2018" } } }, "localname": "OptionsOriginallyScheduledToExpireInFebruaryTwoThousandEighteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_OptionsOriginallyScheduledToExpireInJanuaryTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension of options originally scheduled to expire in January 2018.", "label": "Extension of options originally scheduled to expire in January 2019" } } }, "localname": "OptionsOriginallyScheduledToExpireInJanuaryTwoThousandNineteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_OptionsOriginallyScheduledToExpireInMarchTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension of options originally scheduled to expire in March 2018.", "label": "Extension of options originally scheduled to expire in March 2018" } } }, "localname": "OptionsOriginallyScheduledToExpireInMarchTwoThousandEighteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_OptionsOriginallyScheduledToExpireInMayTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension of options originally scheduled to expire in May 2018.", "label": "Extension of options originally scheduled to expire in May 2018" } } }, "localname": "OptionsOriginallyScheduledToExpireInMayTwoThousandEighteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_OtherCurrenciesExceptUsDollarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for currencies other than U.S. dollars.", "label": "Other Currencies" } } }, "localname": "OtherCurrenciesExceptUsDollarMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_OtherThanDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a person not serving on the board of directors.", "label": "According to the Award Plan of the Company" } } }, "localname": "OtherThanDirectorsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_PayableInRespectOfIntangibleAssetPurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for payable in respect of intangible asset purchase.", "label": "Payable in respect of intangible assets purchase" } } }, "localname": "PayableInRespectOfIntangibleAssetPurchaseMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_PaymentsForProceedsFromNoncurrentBorrowings": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash inflow (outflow) related to non-current borrowings obtained.", "label": "Payments For Proceeds From Noncurrent Borrowings", "negatedLabel": "Proceeds from long-term borrowing, net of transaction costs" } } }, "localname": "PaymentsForProceedsFromNoncurrentBorrowings", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_PercentageOfFeeOnNetRevenueForServicesReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of fee on net revenue for services received.", "label": "Percentage Of Fee On Net Revenue For Services Received", "terseLabel": "Fee on net revenue for services received (as a percent)" } } }, "localname": "PercentageOfFeeOnNetRevenueForServicesReceived", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "percentItemType" }, "rdhl_PercentageOfReasonablyPossibleIncreaseInRiskAssumption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The reasonably possible percentage of the increase in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations.", "label": "Percentage Of Reasonably Possible Increase In Risk Assumption", "terseLabel": "Percentage of currency stronger against the NIS" } } }, "localname": "PercentageOfReasonablyPossibleIncreaseInRiskAssumption", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "percentItemType" }, "rdhl_PeriodForNonDerivativeFinancialLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period for non-derivative financial liabilities.", "label": "Period For Non Derivative Financial Liabilities", "terseLabel": "Period for non-derivative financial liabilities" } } }, "localname": "PeriodForNonDerivativeFinancialLiabilities", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "durationItemType" }, "rdhl_PortfolioConcentrationRiskPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the concentration of portfolio risk from investments in a single bond issuer.", "label": "Portfolio Concentration Risk Percentage", "terseLabel": "Portfolio invested in a single bond issuer (as a percent)" } } }, "localname": "PortfolioConcentrationRiskPercentage", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails" ], "xbrltype": "percentItemType" }, "rdhl_ProceedsFromExerciseOfWarrantsAndOptions": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the exercise of warrants and options.", "label": "Proceeds From Exercise of Warrants and Options", "terseLabel": "Exercise of options into ordinary shares" } } }, "localname": "ProceedsFromExerciseOfWarrantsAndOptions", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_ProductReturnsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stands for Product returns.", "label": "Product returns" } } }, "localname": "ProductReturnsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "domainItemType" }, "rdhl_ProgramRebatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to program rebates.", "label": "Program rebates" } } }, "localname": "ProgramRebatesMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "domainItemType" }, "rdhl_PurchaseOfNonCurrentBankDepositsClassifiedAsInvestingActivities": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the purchase of non-current bank deposit.", "label": "Purchase of Non Current Bank Deposits Classified as Investing Activities", "negatedLabel": "Purchase of non-current bank deposits" } } }, "localname": "PurchaseOfNonCurrentBankDepositsClassifiedAsInvestingActivities", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_QuartersEndingJuneThirtyTwoThousandTwentyTwoAndSeptemberThirtyTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the quarters ending June 30, 2022, and September 30, 2022.", "label": "Quarters ending June 30, 2022, and September 30, 2022" } } }, "localname": "QuartersEndingJuneThirtyTwoThousandTwentyTwoAndSeptemberThirtyTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "rdhl_QuartersEndingJuneThirtyTwoThousandTwentyTwoAndSeptemberThirtyTwoThousandTwentyTwoThereafterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the period after the quarters ending June 30, 2022, and September 30, 2022.", "label": "Thereafter" } } }, "localname": "QuartersEndingJuneThirtyTwoThousandTwentyTwoAndSeptemberThirtyTwoThousandTwentyTwoThereafterMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "rdhl_RebatesAndPatientDiscountProgramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Rebates and patient discount programs.", "label": "Rebates and patient discount programs" } } }, "localname": "RebatesAndPatientDiscountProgramsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "domainItemType" }, "rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of payable in respect of intangible asset purchase", "label": "Repayment of payable in respect of intangible asset purchase", "negatedLabel": "Repayment of payable in respect of intangible asset purchase" } } }, "localname": "RepaymentOfPayableInRespectOfIntangibleAssetPurchase", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_ResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the Research and Development operating segment.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "rdhl_RetunesAndChargebackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertianing to Retunes and Chargeback.", "label": "Retunes and chargeback" } } }, "localname": "RetunesAndChargebackMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "domainItemType" }, "rdhl_RevaluationOfBankDeposits": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 8.0, "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for revaluation of bank deposits.", "label": "Revaluation Of Bank Deposits", "terseLabel": "Revaluation of bank deposits" } } }, "localname": "RevaluationOfBankDeposits", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of reversed expense from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.", "label": "Reversed Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets", "terseLabel": "Shares forfeited, reversed expenses" } } }, "localname": "ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_SaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Sale Of Stock [Axis]" } } }, "localname": "SaleOfStockAxis", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "stringItemType" }, "rdhl_SaleOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock [Domain]" } } }, "localname": "SaleOfStockDomain", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "domainItemType" }, "rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of movement of allowance for deductions from revenues.", "label": "Schedule Of Movement Of Allowance For Deductions From Revenues [Table Text Block]", "terseLabel": "Schedule of movement of allowance for deductions from revenue" } } }, "localname": "ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesTables" ], "xbrltype": "textBlockItemType" }, "rdhl_ScheduleTenderOfferToExchangeOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule tender offer to exchange options.", "label": "Exchange Offer" } } }, "localname": "ScheduleTenderOfferToExchangeOptionsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEqualQuarterlyVestingInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of equal quarterly vesting installments.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Equal Quarterly Vesting Installments", "terseLabel": "Number of equal quarterly vesting installments" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEqualQuarterlyVestingInstallments", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "integerItemType" }, "rdhl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodExtension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the extension of the exercise period of fully-vested options in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Period Extension", "terseLabel": "Extension of the exercise period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePeriodExtension", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "durationItemType" }, "rdhl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The grant date fair value of options.", "label": "Share-based Compensation Arrangement By Share-based Payment Award Options Grant Date Fair Value", "terseLabel": "Fair value of options on date of grant in U.S. dollars in thousands" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_ShareBasedCompensationAwardTrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fourth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.", "label": "Vesting, two years following grant" } } }, "localname": "ShareBasedCompensationAwardTrancheFourMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD" } } }, "localname": "SignificantEventsDuringCurrentReportingPeriodAbstract", "nsuri": "http://www.redhillbio.com/20220630", "xbrltype": "stringItemType" }, "rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of significant events during the current reporting period.", "label": "Significant Events During Current Reporting Period [Text Block]", "terseLabel": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD" } } }, "localname": "SignificantEventsDuringCurrentReportingPeriodTextBlock", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriod" ], "xbrltype": "textBlockItemType" }, "rdhl_SubscriptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Subscription Agreement.", "label": "Subscription Agreement [Member]" } } }, "localname": "SubscriptionAgreementMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "domainItemType" }, "rdhl_SupplementalInformationInterestPaidInCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Supplemental information on interest paid in cash.", "label": "Supplemental Information Interest Paid In Cash", "terseLabel": "SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH" } } }, "localname": "SupplementalInformationInterestPaidInCash", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_SupplementalInformationInterestReceivedInCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Supplemental information on interest received in cash.", "label": "Supplemental Information Interest Received in Cash", "terseLabel": "SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH" } } }, "localname": "SupplementalInformationInterestReceivedInCash", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_SupplementaryInformationOnNonCashInvestingActivitiesPurchaseOfIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Supplementary information on investing activities related to the purchase of intangible assets not involving cash flows.", "label": "Supplementary Information On Non Cash Investing Activities Purchase Of Intangible Assets", "terseLabel": "Purchase of intangible assets posted as payable" } } }, "localname": "SupplementaryInformationOnNonCashInvestingActivitiesPurchaseOfIntangibleAssets", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_TaliciaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Talicia prescription medicine.", "label": "Talicia" } } }, "localname": "TaliciaMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails", "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails", "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodAgreementsDetails" ], "xbrltype": "domainItemType" }, "rdhl_TrailingFourFiscalQuarterPeriodsEndingJuneThirtyTwoThousandTwentyTwoAndSeptemberThirtyTwoThousandTwentyTwoEachFiscalQuarterThereafterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for each fiscal quarter after the trailing four fiscal quarter periods ending June 30, 2022, and September 30, 2022.", "label": "Each fiscal quarter thereafter" } } }, "localname": "TrailingFourFiscalQuarterPeriodsEndingJuneThirtyTwoThousandTwentyTwoAndSeptemberThirtyTwoThousandTwentyTwoEachFiscalQuarterThereafterMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "rdhl_TrailingFourFiscalQuarterPeriodsEndingJuneThirtyTwoThousandTwentyTwoAndSeptemberThirtyTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the trailing four fiscal quarter periods ending June 30, 2022, and September 30, 2022.", "label": "Trailing four fiscal quarter periods ending June 30, 2022, and September 30, 2022" } } }, "localname": "TrailingFourFiscalQuarterPeriodsEndingJuneThirtyTwoThousandTwentyTwoAndSeptemberThirtyTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "rdhl_TransactionCostsRelatedToPurchaseOfIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for transaction costs related to purchase of intangible assets.", "label": "Transaction Costs Related To Purchase Of Intangible Assets", "negatedLabel": "Transaction costs related to purchase of intangible assets" } } }, "localname": "TransactionCostsRelatedToPurchaseOfIntangibleAssets", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rdhl_TransfersBetweenLevelsFairValueHierarchyAssetsAndLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of transfers between levels of the fair value hierarchy.", "label": "Transfers Between Levels Fair Value Hierarchy Assets And Liabilities", "terseLabel": "Transfers between levels 1, 2 or 3 fair value measurements" } } }, "localname": "TransfersBetweenLevelsFairValueHierarchyAssetsAndLiabilities", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "rdhl_TypeOfArrangementTransactionsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of arrangement or agreement, including but not limited to collaborative arrangements.", "label": "Type of Arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementTransactionsAxis", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302022Details" ], "xbrltype": "stringItemType" }, "rdhl_VouchersAndOtherDeductionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to vouchers and other deductions.", "label": "Vouchers and other deductions" } } }, "localname": "VouchersAndOtherDeductionsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" ], "xbrltype": "domainItemType" }, "rdhl_Warrants": { "auth_ref": [], "calculation": { "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of warrants issued.", "label": "Warrants, value", "terseLabel": "Warrants" } } }, "localname": "Warrants", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "rdhl_WarrantsExercisableTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time warrants are exercisable after the issuance date, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrants Exercisable Term", "terseLabel": "Warrants, exercisable term" } } }, "localname": "WarrantsExercisableTerm", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "durationItemType" }, "rdhl_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for a component of equity representing issued warrants.", "label": "Warrants." } } }, "localname": "WarrantsMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsSignificantUnobservableInputsDetails", "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "rdhl_WarrantsNumberIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants issued during the period.", "label": "Warrants, Number Issued", "terseLabel": "Warrants issued" } } }, "localname": "WarrantsNumberIssued", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" ], "xbrltype": "sharesItemType" }, "rdhl_WeightedAverageExercisePriceOfShareOptionsGrantedInShareBasedPaymentArrangementPercentageIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage increase in the weighted average exercise price of share options granted in a share-based payment arrangement.", "label": "Weighted Average Exercise Price Of Share Options Granted In Share-based Payment Arrangement Percentage Increase", "terseLabel": "Exercise price increase (as a percent)" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInShareBasedPaymentArrangementPercentageIncrease", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "percentItemType" }, "rdhl_YearOfGrantTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent the year of grant 2019", "label": "2019" } } }, "localname": "YearOfGrantTwoThousandNineteenMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_YearOfGrantTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the year of grant 2020.", "label": "2020" } } }, "localname": "YearOfGrantTwoThousandTwentyMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_YearOfGrantTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the year of grant 2021.", "label": "2021" } } }, "localname": "YearOfGrantTwoThousandTwentyOneMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "rdhl_YearOfGrantTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the year of grant 2022.", "label": "2022" } } }, "localname": "YearOfGrantTwoThousandTwentyTwoMember", "nsuri": "http://www.redhillbio.com/20220630", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chairman of the Board of Directors" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B36", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B36", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r102": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r103": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE60", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r104": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2021-03-24" }, "r106": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "105", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_105&doctype=Standard", "URIDate": "2021-03-24" }, "r107": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2021-03-24" }, "r108": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "115", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_115&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2021-03-24" }, "r111": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_116_c&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_a&doctype=Standard", "URIDate": "2021-03-24" }, "r113": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r116": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI", "URIDate": "2021-03-24" }, "r118": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r119": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r121": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24" }, "r122": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard", "URIDate": "2021-03-24" }, "r123": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "C12", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C", "URIDate": "2021-03-24" }, "r124": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard", "URIDate": "2021-03-24" }, "r125": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r126": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r127": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2021-03-24" }, "r128": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r129": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2021-03-24" }, "r131": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2021-03-24" }, "r132": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r133": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r134": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r135": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r136": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r137": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2021-03-24" }, "r138": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r139": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "14", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_14_a&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r141": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r142": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r143": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" }, "r144": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r145": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24" }, "r146": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2021-03-24" }, "r147": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r148": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24" }, "r149": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard", "URIDate": "2021-03-24" }, "r151": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "39", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_39&doctype=Standard", "URIDate": "2021-03-24" }, "r152": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2021-03-24" }, "r153": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard", "URIDate": "2021-03-24" }, "r154": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r155": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2021-03-24" }, "r156": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2021-03-24" }, "r157": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2021-03-24" }, "r158": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "8", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_8&doctype=Standard", "URIDate": "2021-03-24" }, "r159": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r161": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B52", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r162": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG40B", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r163": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2021-03-24" }, "r164": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r165": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2021-03-24" }, "r166": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r167": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r168": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2021-03-24" }, "r169": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r170": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r171": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r172": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r173": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r174": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "IG4", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_IG4&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r175": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI", "URIDate": "2021-03-24" }, "r176": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard", "URIDate": "2021-03-24" }, "r177": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2021-03-24" }, "r178": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r179": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard", "URIDate": "2021-03-24" }, "r180": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2021-03-24" }, "r181": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2021-03-24" }, "r182": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_c&doctype=Standard", "URIDate": "2021-03-24" }, "r183": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r184": { "IssueDate": "2021-01-01", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r185": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r186": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_f&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r187": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r188": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r189": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r190": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r191": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-3" }, "r192": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r193": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r194": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r195": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r196": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r197": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2021-03-24" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r3": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "j", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22_j&doctype=Standard", "URIDate": "2021-03-24" }, "r32": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2021-03-24" }, "r33": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_d&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_e&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "134", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_134_d_v&doctype=Standard", "URIDate": "2021-03-24" }, "r51": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "134", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_134_e_v&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "84", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_84&doctype=Standard", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_119_a&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "122", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_122_e&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2021-03-24" }, "r6": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "44C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24" }, "r78": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C__IAS07_IE_C_TI", "URIDate": "2021-03-24" }, "r79": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r81": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r82": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r84": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r85": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r86": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r87": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r88": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2021-03-24" }, "r93": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r95": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2021-03-24" }, "r97": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard", "URIDate": "2021-03-24" }, "r98": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24" }, "r99": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B11", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B11_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" } }, "version": "2.1" }